Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von HC Wainwright 

Clearside Biomedical Inc diskutieren

Clearside Biomedical Inc

WKN: A2ALP6 / Symbol: CLSD / Name: Clearside / Aktie / Micro Cap /

0,27 €
-8,78 %

8 1
8
1
Einschätzung Buy
Rendite (%) -59,81 %
Kursziel 3,69
Veränderung
Endet am 25.07.25

Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $4.00 price target on the stock.
Ratings data for CLSD provided by MarketBeat

Needham & Company LLC 
0
Melden Teilen
25.07.24
Einschätzung Buy
Rendite (%) -60,58 %
Kursziel 4,62
Veränderung
Endet am 30.07.25

Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Ratings data for CLSD provided by MarketBeat

HC Wainwright 
0
Melden Teilen
30.07.24
Einschätzung Buy
Rendite (%) -59,78 %
Kursziel 3,66
Veränderung
Endet am 13.08.25

Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $4.00 price target on the stock.
Ratings data for CLSD provided by MarketBeat

Needham & Company LLC 
0
Melden Teilen
13.08.24
Einschätzung Buy
Rendite (%) -61,05 %
Kursziel 4,54
Veränderung
Endet am 13.08.25

Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Ratings data for CLSD provided by MarketBeat

HC Wainwright 
0
Melden Teilen
13.08.24
Einschätzung Buy
Rendite (%) -61,59 %
Kursziel 5,39
Veränderung
Endet am 21.08.25

Clearside Biomedical, Inc. (NASDAQ: CLSD) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $6.00 price target on the stock.
Ratings data for CLSD provided by MarketBeat

Chardan Capital 
0
Melden Teilen
21.08.24
Einschätzung Buy
Rendite (%) -64,00 %
Kursziel 4,47
Veränderung
Endet am 27.08.25

Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Ratings data for CLSD provided by MarketBeat

HC Wainwright 
0
Melden Teilen
27.08.24
Einschätzung Buy
Rendite (%) -77,17 %
Kursziel 5,48
Veränderung
Endet am 10.10.25

Clearside Biomedical, Inc. (NASDAQ: CLSD) had its price target raised by analysts at Needham & Company LLC from $4.00 to $6.00. They now have a "buy" rating on the stock.
Ratings data for CLSD provided by MarketBeat

Needham & Company LLC 
0
Melden Teilen
10.10.24
Einschätzung Buy
Rendite (%) -73,65 %
Kursziel 5,50
Veränderung
Endet am 14.10.25

Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
Ratings data for CLSD provided by MarketBeat

Chardan Capital 
0
Melden Teilen
14.10.24

Clearside Biomedical, Inc. (NASDAQ: CLSD) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for CLSD provided by MarketBeat

StockNews.com 
0
Melden Teilen
09.11.24 Sell -73,52 %
Einschätzung Buy
Rendite (%) -72,48 %
Kursziel 5,64
Veränderung
Endet am 13.11.25

Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
Ratings data for CLSD provided by MarketBeat

Needham & Company LLC 
0
Melden Teilen
13.11.24
Einschätzung Buy
Rendite (%) -69,79 %
Kursziel 5,70
Veränderung
Endet am 14.11.25

Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Ratings data for CLSD provided by MarketBeat

HC Wainwright 
0
Melden Teilen
14.11.24
Einschätzung Buy
Rendite (%) -66,86 %
Kursziel 5,56
Veränderung
Endet am 06.03.26

Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Ratings data for CLSD provided by MarketBeat

HC Wainwright 
0
Melden Teilen
06.03.25
Einschätzung Buy
Rendite (%) -66,86 %
Kursziel 5,56
Veränderung
Endet am 06.03.26

Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
Ratings data for CLSD provided by MarketBeat

Needham & Company LLC 
0
Melden Teilen
06.03.25
Einschätzung Buy
Rendite (%) -67,49 %
Kursziel 5,56
Veränderung
Endet am 28.03.26

Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
Ratings data for CLSD provided by MarketBeat

Chardan Capital 
0
Melden Teilen
28.03.25
Einschätzung Buy
Rendite (%) -67,49 %
Kursziel 3,71
Veränderung
Endet am 28.03.26

Clearside Biomedical, Inc. (NASDAQ: CLSD) had its price target lowered by analysts at Needham & Company LLC from $6.00 to $4.00. They now have a "buy" rating on the stock.
Ratings data for CLSD provided by MarketBeat

Needham & Company LLC 
0
Melden Teilen
28.03.25
Einschätzung Buy
Rendite (%) -64,85 %
Kursziel 5,53
Veränderung
Endet am 31.03.26

Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Ratings data for CLSD provided by MarketBeat

HC Wainwright 
0
Melden Teilen
31.03.25
Einschätzung Buy
Rendite (%) -59,44 %
Kursziel 3,65
Veränderung
Endet am 08.04.26

Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $4.00 price target on the stock.
Ratings data for CLSD provided by MarketBeat

Needham & Company LLC 
0
Melden Teilen
08.04.25

Clearside Biomedical, Inc. (NASDAQ: CLSD) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for CLSD provided by MarketBeat

StockNews.com 
0
Melden Teilen
10.05.25 Sell -65,75 %
Einschätzung Buy
Rendite (%) -65,75 %
Kursziel 2,68
Veränderung
Endet am 15.05.26

Clearside Biomedical, Inc. (NASDAQ: CLSD) had its price target lowered by analysts at Needham & Company LLC from $4.00 to $3.00. They now have a "buy" rating on the stock.
Ratings data for CLSD provided by MarketBeat

Needham & Company LLC 
0
Melden Teilen
15.05.25
Einschätzung Buy
Rendite (%) -63,95 %
Kursziel 4,42
Veränderung
Endet am 23.05.26

Clearside Biomedical, Inc. (NASDAQ: CLSD) had its price target lowered by analysts at HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.
Ratings data for CLSD provided by MarketBeat

HC Wainwright 
0
Melden Teilen
23.05.25
Noch kein Mitglied? Jetzt kostenlos registrieren!

Neueste Beiträge

StockNews_com in Axcelis Technologies diskutieren
Axcelis Technologies (NASDAQ:ACLS) was upgraded by analy...
14.12.25
StockNews_com in American Superconductor Corp diskutieren
American Superconductor (NASDAQ:AMSC) was upgraded by an...
14.12.25
StockNews_com in Healthcare Services Group diskutieren
Healthcare Services Group (NASDAQ:HCSG) was downgraded b...
14.12.25
StockNews_com in Levi Strauss & Co. diskutieren
Levi Strauss & Co. (NYSE:LEVI) was upgraded by analy...
14.12.25
StockNews_com in Manitowoc Company Inc. diskutieren
Manitowoc (NYSE:MTW) was downgraded by analysts at Wall ...
14.12.25
StockNews_com in Nabors Industries Ltd. diskutieren
Nabors Industries (NYSE:NBR) was upgraded by analysts at...
14.12.25
StockNews_com in SFL Corp. Ltd. diskutieren
SFL (NYSE:SFL) was downgraded by analysts at Wall Street...
14.12.25
StockNews_com in TG Therapeutics Inc. diskutieren
TG Therapeutics (NASDAQ:TGTX) was upgraded by analysts a...
14.12.25
Mehr anzeigen